Rankings
▼
Calendar
EVMN Q3 2025 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena
EVMN
Evommune, Inc.
$319M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
Gross Profit
$10M
96.9% margin
Operating Income
-$13M
-133.3% margin
Net Income
-$12M
-124.8% margin
EPS (Diluted)
$-0.40
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$85M
Total Liabilities
$268M
Stockholders' Equity
-$183M
Cash & Equivalents
$27M
← Q2 2025
All Quarters
